SUCNR1 and metabolic dysfunction-associated steatotic liver disease: Mechanistic studies in cell cultures and animal models show that hepatocyte-released succinate triggers fibrotic changes in the liver through activation of hepatic stellate cells [26, 60], suggesting the potential of SUCNR1 as a target for anti-fibrotic NAFLD treatment [61].